Johnson & Johnson (JNJ, Financial) opened the pharmaceutical earnings season on Tuesday by boosting its full-year sales forecast after posting stronger-than-expected first-quarter results. The announcement comes as the industry prepares for potential tariff shifts under the Trump administration.
The New Jersey-based company reported adjusted earnings of $2.77 per share, beating estimates by $0.19. Revenue came in at $21.9 billion, roughly 2% higher than a year ago and ahead of the $21.57 billion analyst forecast.
JNJ's pharmaceutical division drove the upside, generating $13.9 billion in revenue, surpassing the $13.4 billion consensus. Key products included Darzalex, which brought in $3.2 billion — a 20% year-over-year increase — and Xarelto, which generated $690 million, 33% above last year. Meanwhile, sales of Stelara declined 34% to $1.6 billion as generics enter the market, and Invega Sustenna dropped 15% to $903 million.
MedTech performance was mixed. Cardiovascular sales climbed 16% to $2.1 billion, while orthopedics and electrophysiology posted modest declines.
Despite some pressure from product-specific declines, Johnson & Johnson raised its full-year revenue guidance to between $91.0 billion and $91.8 billion. The company attributed the change in part to the addition of Caplyta following its acquisition of Intra-Cellular Therapies.
